Anti-CRISPR (Acr) proteins are bacteriophage-derived antagonists of CRISPR-Cas systems. To date, Acrs were obtained either by mining sequence databanks or experimentally screening phage collections, both of which yield a limited repertoire of naturally occurring variants. Here, we applied structure-based engineering on AcrIIC1, a broad-spectrum inhibitor of type II-C CRISPR systems, to improve its efficacy and expand its specificity. We first show that fusing exogenous protein domains into AcrIIC1 dramatically enhances inhibition of the natural Neisseria meningitidis Cas9 target. Then, using structure-guided design, we converted AcrIIC1 into AcrX, a potent inhibitor of the type II-A CRISPR-Cas9 from Staphylococcus aureus widely applied for in vivo genome editing. Our work introduces designer Acrs as important biotechnological tools and provides an innovative strategy to safeguard the CRISPR technology.
In this work, we sought to apply protein engineering to design artificial Acrs that exhibit enhanced inhibition potency and expanded target specificity ( Fig. 1 ). As starting point, we used AcrIIC1 14 , a broad-spectrum inhibitor targeting various type II-C Cas9s, including those from Neisseria meningitidis (Nme), Geobacillus stearothermophilus and Campylobacter jejuni.
AcrIIC1 binds the conserved catalytic HNH domain and locks Cas9 in a DNA bindingcompetent, but catalytically inactive state. This unique inhibitory mechanism might explain why AcrIIC1 is a rather weak inhibitor 15 as compared to its related proteins AcrIIC3, -C4 and -C5, all of which interfere with Cas9 DNA binding. Importantly, biochemical assays suggest tight binding of AcrIIC1 to the NmeCas9 HNH domain (K D ~ 6.3 nM (Ref. 2)), indicating that it is the inhibitory mechanism rather than the affinity which leads to the suboptimal performance of AcrIIC1.
We hypothesized that inserting a sufficiently large, exogenous domain into AcrIIC1 could result in an inhibitor that would still bind tightly to the HNH domain, but -on top of inhibiting Cas9 catalytic activity -could block additional, important mechanistic steps such as DNA binding ( Fig. 1, left) . To test this hypothesis, we first created a structural model of the AcrIIC1-Cas9-sgRNA complex (see Methods for details) and interrogated it for AcrIIC1 surface sites that could be amenable for engineering. AcrIIC1 loop 5 appeared to be an ideal candidate ( Supplementary   Fig. 1 ), as it is located close to the DNA binding groove when assuming the HNH-docked Cas9 state 19 , but distal from the HNH-interacting surface necessary for activity that we wished to preserve. We then created 11 different AcrIIC1 domain fusions which carry either an mCherry (~27 kDa), Avena sativa LOV2 (~17 kDa) or PDZ domain (~9 kDa) at different positions in loop 4 Acrs were screened by T7 endonuclease assay for their ability to inhibit NmeCas9 cleavage of the IL2RG locus in HEK 293T cells ( Supplementary Fig. 2b ). Remarkably, several AcrIIC1-LOV2 and AcrIIC1-mCherry chimeras mediated highly potent NmeCas9 inhibition largely exceeding that of the parent AcrIIC1 ( Fig. 2a,b, Supplementary Figs. 2b and 3) . The AcrIIC1-mCherry chimera #10 (GSG-mCherry-GSG inserted between AcrIIC1 residues Y70 and A71; Supplementary Fig. 2a ) showed an improvement superior to 12-fold in NmeCas9 inhibition as compared to wild-type AcrIIC1 on the four tested loci ( Fig. 2a and b ), and performed equivalently or better than AcrIIC3, so-far the most potent NmeCas9 inhibitor in mammalian cells 14 (Fig. 2b) .
To further characterize the gain in inhibition, we employed a reporter assay in which NmeCas9 cleaves a firefly luciferase transgene, thereby resulting in luciferase knockout. We co-transfected cells with the reporter, NmeCas9 and either (i) the parent AcrIIC1, (ii) the AcrIIC3 benchmark or (iii) different, engineered AcrIIC1-mCherry chimeras. During transfection, we varied the Acr:Cas9 vector ratios from 3:1 to 1:20. The chimeric inhibitors outperformed both, wild-type AcrIIC1 as well as AcrIIC3 and showed potent Cas9 inhibition even at very low Acr:Cas9 vector ratios ( Fig. 2c ).
To elucidate this particularly efficient inhibitory mechanism, we performed an assay in which the firefly luciferase gene was targeted by a NmeCas9 nickase carrying an impaired RuvC, but a wild-type HNH domain (see Supplementary Note for details). Luciferase activity was potently rescued in the presence of the AcrIIC1-mCherry chimeric inhibitor, comparable to the AcrIIC3 benchmark ( Supplementary Fig. 4 ). Notably, AcrIIC1 also mediated some rescue of luciferase activity, reaching precisely the level observed when targeting the same reporter with a catalytically dead (d)NmeCas9 which inhibits firefly luciferase expression exclusively via CRISPR interference ( Supplementary Fig. 4 ). This suggests that on top of blocking the catalytic activity (akin to native AcrIIC1), the chimeric inhibitors also interfere -at least to some extentwith NmeCas9 DNA binding (see Supplementary Note). Together, these experiments demonstrate that domain insertion can yield anti-CRISPR proteins with far superior inhibition potency than that of natural anti-CRISPRs, thereby enabling extremely tight control of Cas9.
Having shown that AcrIIC1 could be modified to enhance its potency, we next aimed to expand its specificity. The Cas9 from Staphylococcus aureus is a type II-A CRISPR effector widely employed for in vivo genome editing 20 . Due to its favorable, small size (3.2 kb), Staphylococcus aureus (Sau)Cas9 can easily be packaged into Adeno-associated virus (AAV) particles 20 , which are prime vector candidates for therapeutic CRISPR applications 21, 22 . Importantly, no anti-CRISPR proteins have yet been discovered that would allow blocking SauCas9 activity. We speculated that AcrIIC1 might represent an ideal starting point to engineer an artificial SauCas9 inhibitor, as the overall fold of the SauCas9 HNH domain is similar to that of NmeCas9 19 , albeit substantial differences exist at the sequence level (sequence identity is only 33.7 %, Supplementary Fig. 5 ). Recent in vitro data suggest that wild-type AcrIIC1 fails to inhibit SauCas9 function 23 . To independently confirm this finding, we co-expressed AcrIIC1 in HEK 293T cells together with SauCas9 and sgRNAs targeting different loci and performed T7 endonuclease assays to detect formation of insertions and deletions (indels). Strikingly, we observed a reproducible, albeit rather mild reduction of indels in the AcrIIC1 samples to about 50 % of the positive controls ( Supplementary Fig. 6 ), indicating that AcrIIC1 can also bind the SauCas9 HNH domain, though likely with a compromised affinity.
Based on this assumption we sought to enhance SauCas9 binding. We generated a structural model of SauCas9 HNH domain in complex with AcrIIC1 and investigated the differences in the AcrIIC1 interacting surface as compared to the NmeCas9 HNH ( Fig. 3 ). Two regions in SauCas9 HNH domain showed suboptimal contacts to corresponding AcrIIC1 residues ( Fig. 3 ). We then performed per-residue in silico mutagenesis using Rosetta design 24 followed by manual inspection, which suggested ten AcrIIC1 candidate mutations to improve binding to the SauCas9 HNH domain ( Supplementary Figs. 7 and 8 ). We tested these mutants, first individually, in genome editing experiments targeting the EMX1 locus and then iteratively combined the most promising variants in subsequent screening rounds (Supplementary Fig. 9 ). Of note, we decreased the Acr:Cas9 ratio with each screening round to better resolve the performance of improving candidates. After only three rounds, we arrived at a triple mutant (N3F, D15Q, A48I; Fig. 3 and Supplementary Fig. 10 ), which we confirmed to be well folded in solution ( Supplementary Fig. 11 ) and which achieved a near-complete blocking of EMX1 editing by SauCas9 ( Supplementary Fig. 9 ). Remarkably, this mutant also retained NmeCas9 inhibitory activity comparable to wild-type AcrIIC1 ( Supplementary Fig. 12 , NmeCas9 samples), indicating that our engineering approach had not just re-targeted AcrIIC1 to SauCas9, but rather expanded its specificity towards this orthologue. We therefore named the mutant AcrX for its ability to target both, type II-C and II-A CRISPR effectors, which -to our best knowledge -has not yet been observed for any natural Acr.
Next, we characterized AcrX performance in detail by targeting SauCas9 to different loci ( Fig.   4a ). AcrX efficiently suppressed SauCas9 genome editing at all tested loci, showing up to a ~30fold improvement in inhibition as compared to the parental AcrIIC1 ( Fig. 4b , Supplementary
Figs. 13 and 14) . Interestingly, akin to wild-type AcrIIC1, mCherry domain fusion to AcrX loop 5 strongly improved inhibition on NmeCas9 ( Supplementary Fig. 12 ), but had no noticeable effect on SauCas9 inhibition. This indicates that the potent inhibition mediated by our chimeric Acrs arises from specific features of the NmeCas9 structural architecture.
Finally, to test the performance of AcrX in different mammalian cell lines and upon viral delivery, we packaged (i) AcrX as well as (ii) SauCas9 and sgRNAs targeting the EMX1, Grin2B or CXCR4 locus into AAV serotype 2. We then transduced HEK 293T (human embryonic kidney), U2OS (human osteosarcoma) or U87 (human primary glioblastoma) cells with these vectors and found that indel formation was reduced to undetectable levels in practically all samples that received AcrX (Fig. 4c ).
Here, we reported the engineering of anti-CRISPR proteins with improved inhibition potency and expanded target specificity. We showed that domain insertion into AcrIIC1 enhances NmeCas9 inhibition, likely by interfering with DNA binding. On top, using structure-based design, we created the first anti-CRISPR protein able to efficiently block SauCas9 function. Our findings show that structure-guided protein engineering can yield anti-CRISPR proteins with desired properties that go beyond the currently known natural repertoire. These designer anti-CRISPRs might not only find wide application in the context of biotechnology and CRISPRbased therapies 7-10 , but also provide an innovative strategy to safeguard CRISPR technology.
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Seamon targeting the indicated loci followed by T7 endonuclease assay. The Acr:Cas9 vector ratio used during transfection is indicated. P denotes a T7 cleavage band which is due to a polymorphism in the CCR5 gene ( Supplementary Fig. 15 ). In., input band. T7 frag., T7 cleavage fragments. 
Online Methods

Modeling of AcrIIC1-mCherry fusions
We used the Rosetta remodel application 25 to generate the AcrIIC1-mCherry chimeras based on the structures for AcrIIC1 (PDB 5VGB) and mCherry (PDB 4ZIN). The N-and C-termini of mCherry were absent in the crystal structure and were rebuilt using fragment insertion together with cyclic coordinate descent 26 illustrate the potential structural diversity of the AcrIIC1-mCherry chimeras ( Supplementary Fig.   3 ). Analysis of the Rosetta outputs, structural models and the biochemical data was performed using the rstoolbox 29 .
AcrIIC1 interface design
To screen in silico for mutations that could enhance the affinity of AcrIIC1 to Staphylococcus aureus (Sau)Cas9, we modeled a complex of AcrIIC1 (originally crystalized with the HNH domain of Neisseria meningitidis (Nme)Cas9, PDB 5VGB) with the SauCas9 HNH domain (PDB 5CZZ). A first structural alignment was performed between the Nme and SauCas9 domains using TM-align 30 revealing an r.m.s.d of 2.32 Å and several structurally and sequenceconserved interface regions. These conserved interface regions were then used to refine the alignment, using the PyMOL (version 2.3.1) superposition function, to obtain the modeled complex used for the design simulations ( Supplementary Fig. 5 ). We then analyzed the interfaces of both orthologues to pinpoint hotspots which could be designed in AcrIIC1 to enhance its interaction with SauCas9. These hotspots were visualized with surface point-wise distances between the two surfaces that were computed with a custom script. For each point on the reference surface (Nme), the distance to the closest point on the other surface (Sau) was calculated. In the visualizations, these distances were binarized by setting a cutoff of 1 Å (Fig.   3 ).
Next, we used RosettaScripts 31 to perform a single-site in silico mutagenesis, thereby allowing subsets of amino acids for each of the selected residues on AcrIIC1. From our interface analysis we selected the following residues in AcrIIC1 for in silico mutagenesis: N3, D15, R36, D43, were designed to increase interface packing and pi-stacking with the complementary hydrophobic patches on SauCas9. D43F and D45F were generated to fill voids within the interface boundaries and increase the hydrophobic packing. D15Q, R36D, D46E, K47Q and M77S were introduced to balance the underlying charge distribution on SauCas9 within the respective region. The overall design workflow is shown in Supplementary Fig. 7 .
After experimental validation and combination of the proposed mutations, the final AcrX (AcrIIC1 with N3F, D15Q, A48I) was modeled following the same protocol. Electrostatic properties for AcrIIC1, AcrX as well as the NmeCas9 and the SauCas9 HNH domains were computed using the adaptive Poisson Boltzmann solver (APBS) plugin in PyMOL ( Supplementary Fig. 10 ). The mutation D15Q results in a less negative potential, to optimize the interaction with a patch of the interface in SauCas9 that has a lower positive potential as compared to NmeCas9.
Protein expression and purification
DNA sequences of the designs were purchased from Twist Bioscience. For bacterial expression, the DNA fragments were cloned via Gibson cloning 32 
Circular dichroism (CD)
Far-UV circular dichroism spectra of AcrIIC1 and AcrX were collected between a wavelength of 190 nm to 250 nm on a Jasco J-815 CD spectrometer in a 1 mm path-length quartz cuvette.
Proteins were dissolved in 10 mM phosphate buffer at concentrations between 20 μM and 40 μM. Wavelength spectra were averaged from two scans with a scanning speed of 20 nm per min and a response time of 0.125 sec. The thermal denaturation curves were collected by measuring the change in ellipticity at 220 nm from 20 to 90°C with 2 or 5°C increments.
Size-exclusion chromatography combined with Multi-Angle Light-Scattering (SEC-MALS)
Multi 
Construct design and cloning
Constructs used in this study are listed in Supplementary Table 1 . Sequences for all plasmids created in this study are provided as GenBank files in Supplementary Data. The following constructs were generated via classical restriction enzyme cloning or Golden Gate assembly 33 . The plasmid pEJS654 All-in-One AAV-sgRNA-hNmeCas9 co-encoding NmeCas9 and a corresponding sgRNA expression cassette was a kind gift from Erik Sontheimer (Addgene #112139). The plasmid pX601-AAV-CMV::NLS-SaCas9-NLS-3xHA-bGHpA;U6::BsaI-sgRNA co-encoding SauCas9 and a corresponding sgRNA expression cassette was a kind gift from Feng Zhang (Addgene #61591). The luciferase reporter plasmid was previously reported by us 8 and modified as follows: an NTS33 target site 34 was inserted behind the firefly luciferase start codon and in frame with the luciferase gene; an NTS33-targeting sgRNA was subsequently inserted into the modified reporter. Vectors encoding AcrIIC1, AcrIIC3 and AcrIIA4 were previously reported by us 8, 9 . AsLOV2-, PDZ-and mCherry-encoding sequences were obtained from IDT as human-codon-optimized synthetic DNA fragments (gBlocks). AcrIIC1 chimeras were created by Golden Gate cloning as follows: the plasmid encoding AcrIIC1 was first linearized at a selected position in the AcrIIC1 coding sequence via around-the-horn PCR; LOV2-, PDZ-and mCherrycoding sequences were then amplified by matching primers introducing optional GS linker encoding sequences and ligated into the linearized vector backbone; point mutations and protein tags were introduced via around-the-horn PCR via the primer overhangs. Annealed oligonucleotides corresponding to the target site sequence were cloned into the hybrid Cas9-sgRNA vectors via SapI (NmeCas9) or BsaI (SauCas9) restriction sites as described previously 20, 34 . Supplementary Fig. 4 ), 33 ng of the dual luciferase reporter, 33 ng of d-or nNmeCas9 and 33 ng Acr construct were co-transfected. Transfections were performed using Lipofectamine 3000 reagent (Thermo Fisher Scientific) according to the manufacturer's protocol.
Cell culture and AAV lysate production
Two days post-transfection, the cells were washed with 1x PBS and lysed with 30 µl passive lysis buffer (Promega) for 30 min, while being shaken on a thermomixer (Eppendorf) at 500 rpm and at room temperature. Finally, luciferase activity was analyzed using the Dual-Glo luciferase assay system (Promega). In short, 10 µl of lysate were transferred to a white sample plate and photo counts were measured with a GLOMAX 96 microplate luminometer (Promega).
Integration time was 10 s with a delay of 2 s between substrate injection and measurement. To calculate the reported luciferase activity values, firefly luciferase photon counts were normalized those obtained for Renilla luciferase.
T7 endonuclease assay and TIDE sequencing
Genomic target sites relevant for T7 and TIDE experiments are listed in Supplementary Table 2 .
For transfection-based experiments, HEK 293T cells were seeded in 96-well plates (Eppendorf) at a density of 12,500 cells per well. For AAV transduction-based experiments, HEK 293T, U2OS and U87 cells were seeded at a density of 3,500, 3,000 and 3,000 cells per well, respectively. For experiments with SauCas9 (Fig 4b, Supplementary Figs. 13 and 14) , transfections were performed with JetPrime using 0.3 µl of JetPrime reagent per well, except for the experiment shown in Supplementary Fig. 12 , in which Lipofectamine 3000 was employed for transfection of all samples including those with SauCas9. Note that the CXCR4 target site in Supplementary Fig. 13 is the CXCR4-1 site in Supplementary Table 2 . For NmeCas9 experiments ( Fig. 2a,b For AAV-based experiments (Fig. 4c) , cells were co-transduced with 50 µl of AcrX and 50 µl Cas9/sgRNA AAV lysates on two subsequent days. As negative and positive controls, cells were transduced with 50 µl of Cas9-only AAV lysate or Cas9/sgRNA AAV lysate (see above), respectively, topped up to 100 µl with PBS (to keep the transduction volume identical in all samples). Note, the CXCR4-target site in Fig. 4c is the CXCR4-2 site in Supplementary Table 2 .
Three days post-transfection or (initial) transduction, cells were harvested in DirectPCR Lysis Reagent (Peqlab) supplemented with Proteinase K (Sigma), and incubated at 55°C for at least 6 hours followed by Proteinase K inactivation at 85°C for 45 min. The CRISPR-Cas9-targeted genomic loci were then amplified via PCR with appropriate primers (Supplementary Table 3) using Q5 Hot Start High-Fidelity DNA Polymerase (New England Biolabs). Indel frequencies were assessed by T7 endonuclease assay or TIDE sequencing 36 .
For T7 assays, 5 µl of the target amplicons were diluted 1:4 in 1x NEB buffer 2 and subsequently denatured at 95°C for 5 min and re-annealed by applying a ramp rate of -2°C per sec at 95 to 85°C and -0.1°C per sec at 85 to 25°C using a nexus GSX1 Mastercycler (Eppendorf).
Subsequently, 0.5 µl of T7 endonuclease (New England Biolabs) was added, and samples were incubated at 37°C for 15 min, followed by analysis on a 2% TBE agarose gel. The PCR input and T7 cleavage fragment bands were then quantified using the gel analysis tool in ImageJ 37, 38 (http://imagej.nih.gov/ij/). The frequency of insertions and deletions was calculated using the formula indel(%) = 100 x (1 -(1-fraction cleaved) 1/2 ), whereas the fraction cleaved = Sum(cleavage product bands)/Sum(cleavage product bands + PCR input band). Full-length gel images are shown in Supplementary Fig. 16 .
For TIDE sequencing analysis, the target locus PCR amplicon was purified from a 1% agarose gel using the QIAquick Gel Extraction Kit (Qiagen). The DNA concentration was determined using a nano-photometer (Nanodrop, Thermo Fisher Scientific) and DNA was diluted to a final concentration of 75 ng per µl and sent for Sanger sequencing (Eurofins, Germany). Percentages of modified sequences were then quantified using the TIDE web tool (https://tide.deskgen.com/).
Statistical analysis
Individual data points correspond to independent experiments with cells that were seeded and transfected/transduced independently and on different days. Each data point shown for the luciferase experiments further represents the mean of three technical replicates, i.e. cell cultures in different wells that were transfected and treated in parallel. Reported differences between groups were analyzed for statistical significance by one-way ANOVA and Bonferroni´s corrected post-hoc test. One, two, three and four asterisks thereby indicated P values below 0.05, 0.01, 0.001 and 0.0001, respectively. P values < 0.05 were considered statistically significant.
Reporting Summary
Further information on experimental design is available in the Life Sciences Reporting Summary linked to this article.
Data and code availability
Vectors encoding AcrX, AcrX* as well as the AcrIIC1-mCherry chimera will be made available via Addgene (plasmids # 128112-128114). Annotated vector sequences (GenBank files) are provided in Supplementary Data. Code and data for the computational domain assembly and the design of the improved AcrIIC1 point mutants will be made available on GitHub
